Primary central nervous system lymphoma is an aggressive extranodal non-Hodgkin lymphoma confined to the CNS compartments (brain, spinal cord, leptomeninges, or eyes) at diagnosis.
The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration BTK inhibitor regimen for CLL/SLL and cleared monthly dosing for amivantamab in EGFR-mutated NSCLC. Additional regulatory reviews are underway for PCNSL and breast cancer treatments.
Researchers have developed modified CAR T cells that overcome prostaglandin E2 suppression in solid tumors and a selective therapy targeting IGHV4-34 that spares healthy immune cells, addressing key limitations in current treatments.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07406230 |
Methotrexate Early Toxicity Monitoring |
NOT_YET_RECRUITING | NA |
| NCT07350850 |
A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort) |
RECRUITING | PHASE2 |
| NCT07185373 |
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07082868 |
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) |
RECRUITING | PHASE1 |
| NCT06940791 |
Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104) |
RECRUITING | PHASE2 |
| NCT06922604 |
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma |
RECRUITING | PHASE1 |
| NCT06832267 |
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL |
RECRUITING | NA |
| NCT06830421 |
Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients |
RECRUITING | PHASE3 |
| NCT06712810 |
Q702 for the Treatment of Patients With Hematologic Malignancies |
RECRUITING | PHASE1 |
| NCT06541665 |
Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL |
ACTIVE_NOT_RECRUITING | PHASE1 |
